ClinicalTrials.govpublic full text
Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC
breast cancer, tesetaxel, capecitabine, her2 negative, combination of tesetaxel and capecitabine, taxane-naive, locally advanced or metastatic breast cancer, hormone receptor positive, metastatic breast cancer (mbc), central nervous system (cns) metastases, de novo metastatic breast cancer, oral chemotherapy
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 905221
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.